Joana Carvalho, PhD, managing science editor —

Joana holds a bachelor’s in biology, a Master of Science in evolutionary and developmental biology, and a PhD in biomedical sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — those that make up the lining of blood vessels — found in the umbilical cord of newborns. In addition to several research fellowships, she was awarded two Erasmus scholarships to conduct part of her studies in France.

Articles by Joana Carvalho

Use of Vertex’s Orkambi and Symdeko To Be Reimbursed in Switzerland

Vertex Pharmaceuticals announced that a reimbursement program covering Orkambi (lumacaftor/ivacaftor) and Symdeko (tezacaftor/ivacaftor combo) will be opening for eligible cystic fibrosis patients (CF) living in Switzerland. The program is part of a recent agreement reached between the company and the Swiss Federal Office of Public Health (FOPH) and…

Nanoparticles with Plant Sterols May Aid Gene Therapy for CF

Tiny particles, or nanoparticles, work better as transport and delivery vehicles for the RNA molecules central to some forms of gene therapy when plant-based relatives of cholesterol, called phytosterols, are included, scientists report. These findings are in the study, “Naturally-occurring cholesterol analogues in lipid nanoparticles…

Top 10 Cystic Fibrosis Stories of 2019

Cystic Fibrosis News Today brought you daily coverage of important discoveries, treatment developments, clinical trials, and other important events related to cystic fibrosis (CF) throughout 2019. As we look forward to bringing you more CF news this year, we present our 10 most-read stories of 2019. No. 10 –…

Your CF Community

Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.